Cover Image

Imaxio SA- 產品平台檢討

Imaxio SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 329429
出版日期 內容資訊 英文 23 Pages
Back to Top
Imaxio SA- 產品平台檢討 Imaxio SA - Product Pipeline Review - 2015
出版日期: 2015年03月31日 內容資訊: 英文 23 Pages

Imaxio SA是總公司設置於法國的生物科技企業,從事針對疫苗及基因學領域的研究開發。藉由人體或動物用載體蛋白質萃取重組疫苗技術來開發鉤端螺旋體病及威爾遜氏病的疫苗。另外也提供API等。

本報告提供Imaxio SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。


Imaxio SA的基本資料

  • Imaxio SA概要
  • 主要資訊
  • 企業資料

Imaxio SA:R&D概要

  • 主要的治療範圍

Imaxio SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Imaxio SA:開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Imaxio SA:藥物簡介

  • IMX-313-TB
  • IMX-313-ML
  • IMX-313-SA
  • IMX-313-IF

Imaxio SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

Imaxio SA:開發暫停中的計劃

Imaxio SA:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司



Product Code: GMDHC06885CDB


Global Markets Direct's, 'Imaxio SA - Product Pipeline Review - 2015', provides an overview of the Imaxio SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Imaxio SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Imaxio SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Imaxio SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Imaxio SA's pipeline products

Reasons to buy

  • Evaluate Imaxio SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Imaxio SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Imaxio SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Imaxio SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Imaxio SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Imaxio SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Imaxio SA Snapshot
    • Imaxio SA Overview
    • Key Information
    • Key Facts
  • Imaxio SA - Research and Development Overview
    • Key Therapeutic Areas
  • Imaxio SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Imaxio SA - Pipeline Products Glance
    • Imaxio SA - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Imaxio SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
    • Imaxio SA - Drug Profiles
    • IMX-313-TB
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMX-313-ML
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMX-313-SA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMX-313-IF
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Imaxio SA - Pipeline Analysis
    • Imaxio SA - Pipeline Products by Target
    • Imaxio SA - Pipeline Products by Route of Administration
    • Imaxio SA - Pipeline Products by Molecule Type
  • Imaxio SA - Recent Pipeline Updates
  • Imaxio SA - Dormant Projects
  • Imaxio SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Imaxio SA, Key Information
  • Imaxio SA, Key Facts
  • Imaxio SA - Pipeline by Indication, 2015
  • Imaxio SA - Pipeline by Stage of Development, 2015
  • Imaxio SA - Monotherapy Products in Pipeline, 2015
  • Imaxio SA - Phase I, 2015
  • Imaxio SA - Preclinical, 2015
  • Imaxio SA - Discovery, 2015
  • Imaxio SA - Pipeline by Target, 2015
  • Imaxio SA - Pipeline by Route of Administration, 2015
  • Imaxio SA - Pipeline by Molecule Type, 2015
  • Imaxio SA - Recent Pipeline Updates, 2015
  • Imaxio SA - Dormant Developmental Projects,2015
  • Imaxio SA, Subsidiaries

List of Figures

  • Imaxio SA - Pipeline by Top 10 Indication, 2015
  • Imaxio SA - Pipeline by Stage of Development, 2015
  • Imaxio SA - Monotherapy Products in Pipeline, 2015
  • Imaxio SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top